Inicio de sesión
Selecionar página

Publicaciones

​A continuación, se referencian las 15 publicaciones más destacadas del grupo de investigación de los últimos 10 años. (*) Autor correspondencia; (‡) igual contribución.

1.      Berenguer J (*), Jarrín I, Bellón JM, Díez C, Jiménez-Sousa MA, Roca C, González-García J, Dalmau D, Olalla J, Herrero C, Villarroya F, Domingo P, Resino S. Obesity-related SNPs and weight gain following first-line antiretroviral therapy. Clin Inf Dis. 2023, online ahead of print (A; FI= 20.99; D1, Infectious Diseases; JCR 2021). PMID: 36345912 DOI: 10.1093/cid/ciac880.

  1. 2.      Salgüero S, Brochado-Kith O, Virseda Verdices A, Berenguer J, González-García J, Martínez I, Díez C, Hontañón V, Pérez-Latorre L, Fernández-Rodríguez A (‡), Jiménez-Sousa MA (‡,*), and  Resino S (‡, *). PBMCs gene expression signature of advanced cirrhosis with high risk for clinically significant portal hypertension in HIV/HCV coinfected patients: A cross-control study. Biomed Pharmacother 2023, 159:114220. (A; FI= 7.42; D1, Pharmacology & Pharmacy; JCR 2021). PMID: 36628818. DOI: 10.1016/j.biopha.2023.114220.
  2. 3.      Sepúlveda-Crespo D, Treviño-Nakoura A, Bellon JM, Ardizone Jiménez B, Jiménez‑Sousa MA, Fernández-Rodríguez A, Martínez I (‡), Resino S (*‡). Meta-analysis: diagnostic accuracy of hepatitis C core antigen detection during therapy with direct-acting antivirals. Aliment Pharmacol Ther 2023; 56 (8): 1224-1234 (A; FI= 9.52; D1, Pharmacology & Pharmacy; JCR 2021). PMID: 36031747. DOI: 10.1111/apt.17198.
  3. 4.      Martin-Vicente M, Almansa R, Martínez I, Tedim AP, Bustamante E, Tamayo L, Aldecoa C, Gómez JM, Renedo G, Berezo JA, Cedeño JA, Mamolar N, García Olivares P, Herrán-Monge R, Cicuendez R, Enríquez P, Ortega A, Jorge N, Doncel C, Fuente A, Bustamante-Munguira J, Muñoz-Gómez MJ, González-Rivera M, Puertas C, Más V, Vázquez M, Pérez-García F, Rico-Feijoo J, Martín S, Motos A, Fernandez-Barat L, Eiros JM, Domínguez-Gil M, Ferrer R, Barbé F, Trapiello W, Kelvin DJ (¥), Bermejo-Martin JF (* ¥), Resino S (¥), Torres A (* ¥). Low anti-SARS-CoV-2 S antibody levels predict increased mortality and dissemination of viral components in the blood of critical COVID-19 patients. J Intern Med. 2022, 291(2):232–240. (A; FI= 13.07; D1, Medicine, General & Internal; JCR 2021). PMID: 34611927. DOI: 10.1111/joim.13386.
  4. 5.      Berenguer J (*), Díez C, Martín-Vicente M, Mican R, Pérez-Elías MJ, García-Fraile LJ, Vidal F, Suárez-García I, Podzamcer D, Del Romero J, Pulido F, Iribarren JA, Gutiérrez F, Poveda E, Galera C, Izquierdo R, Asensi V, Portilla J, López JC, Arribas JR, Moreno S, González-García J, Resino S (‡), Jarrín I (‡). Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort. Clin Microbiol Infect. 2021, 27(11):1678-1684. (A; FI= 13.31; D1, Microbiology; JCR 2021). PMID: 34186209 DOI: 10.1016/j.cmi.2021.06.023.
  5. 6.      Álvaro-Meca A, Goez MC, Resino R, Matías V, Sepúlveda-Crespo D; Martínez I, Resino S (*). Environmental factors linked to hospital admissions in young children due to acute viral lower respiratory infections: a bidirectional case-crossover study. Environ Res. 2022. 212(Pt B), 113319. (A; FI= 8.43; D1, Public, Environmental & Occupational Health; JCR 2021). PMID: 35447151. DOI: 10.1016/j.envres.2022.113319.
  6. 7.      Ryan P, Valencia J, Cuevas G, Torres-Macho J, Troya J, Pueyo A, Muñoz-Gómez MJ, Muñoz-Rivas N, Vázquez-Morón S, Martínez, I, Lazarus JV, Resino S (*). Detection of active hepatitis C in a single visit and link-to-care among excluded people using a mobile unit in Madrid, Spain. Int J Drug Policy. 2021, 96:103424. (A; FI= 5.93; Q1, Substance Abuse; JCR 2021). PMID: 34429222 DOI: 10.1016/j.drugpo.2021.103424.
  7. 8.      Ryan P, Valencia J, Cuevas G; Troya J; Torres-Macho J; Muñoz-Gómez MJ, Muñoz-Rivas N, Canorea I, Vázquez-Morón S (‡), Resino S (‡ *). HIV screening and retention in care in people who use drugs in Madrid, Spain: A prospective study. Infect Dis Poverty. 2021; 10(1): 111. (A; FI= 10.49; D1, Tropical Medicine; JCR 2021). PMID: 34412695. DOI: 10.1186/s40249-021-00894-5.
  8. 9.      Brochado O, Martínez I (*), Berenguer J, Medrano L, González-García J, Jiménez-Sousa MA, Carrero A, Hontañón V, Navarro J, Guardiola JM, Pérez-Latorre L, Micán R, Fernández-Rodríguez A (‡), Resino S (* ‡). HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients. J Biomed Sci 2021; 28:23 (A; FI= 12.77; D1, Medicine, Research & Experimental; JCR 2021). PMID: 33785040. DOI: 10.1186/s12929-021-00718-6.
  9. 10.      Brochado-Kith O, Martínez I, Berenguer J, González-García J, Salgüero S, Sepúlveda-Crespo D, Díez C, Hontañón V, Ibañez-Samaniego L, Pérez-Latorre L, Fernández-Rodríguez A (‡), Jiménez-Sousa MA (‡), Resino S (‡ *). HCV cure with direct-acting antivirals improves liver and immunological markers in HIV/HCV-coinfected patients. Front immunol. 2021; 12:723196. (A; FI= 8.79; Q1, Immunology; JCR 2021). PMID: 34497613. DOI: 10.3389/fimmu.2021.723196.
  10. 11.      García-Broncano P, Medrano LM, Berenguer J, Brochado O, González-García J, Jiménez-Sousa MA, Quereda C, Sanz J, Téllez MJ, Díaz L, Jiménez JL, Muñoz-Fernández MA, Resino S (*). Mild profile improvement of immune biomarkers in HIV/HCV-coinfected patients who removed hepatitis C after HCV treatment: a prospective study. J Infect 2020; 80(1):99-110. (A; FI= 6.07; Q1, Infectious Diseases; JCR 2020). PMID: 31585189. DOI: 10.1016/j.jinf.2019.09.020.
  11. 12.      García-Álvarez M, Pineda-Tenor D, Jiménez-Sousa Ma, Fernández-Rodríguez A, Guzmán-Fulgencio M; Resino S (*). Relationship of vitamin D status with advanced liver fibrosis and response to hepatitis C virus therapy: A meta-analysis. Hepatology. 2014, 6(5):1541-1550. (A; FI= 11.05; D1, Gastroenterology & Hepatology; JCR 2014). PMID: 24975775. DOI: 10.1002/hep.27281.
  12. 13.      Pineda-Tenor D, Berenguer J, Jiménez-Sousa MA, García-Álvarez M, Aldamiz-Echevarría T, Carrero A, Vázquez-Morón S, García-Broncano P, Diez C, Tejerina F, Guzmán-Fulgencio M, Resino S (*). FTO rs9939609 polymorphism is associated with metabolic disturbances and response to HCV therapy in HIV/HCV-coinfected patients. BMC Med. 2014, 12:198. (A; FI= 7.34; D1, Medicine, General & Internal; JCR 2014). PMID: 25367448. DOI: 10.1186/s12916-014-0198-y.
  13. 14.      Guzmán-Fulgencio M, Berenguer J; Rallón N, Fernández-Rodríguez A, Miralles P, Soriano V, Jiménez-Sousa MA, Cosin J, Medrano J, García-Álvarez M, López JC, Benito JM, Resino S (*). HLA-E variants are associated with sustained virological response in HIV/hepatitis C virus-coinfected patients on hepatitis C virus therapy. AIDS 2013; 27(8):1231-1238. (A; FI= 6.55; D1, Infectious Diseases; JCR 2013). PMID: 23811951. DOI: 10.1097/QAD.0b013e32835f5b9c.
  14. 15.      ​Guzmán-Fulgencio M; Berenguer J, Micheloud D, Fernández-Rodríguez A; García–Álvarez M, Jiménez-Sousa MA, Bellón JM, Campos Y, Cosin J, Aldámiz-Echevarría T, Catalán P, López JC, Resino S (*). European mitochondrial haplogroups are associated with CD4+ T-cell recovery in HIV-infected patients on combination antiretroviral therapy. J Antimicrob Chemoth 2013; 68 (10): 2349–2357 (A; FI= 5.44; D1, Infectious Diseases; JCR 2013). PMID: 23749950. DOI: 10.1093/jac/dkt206.




Imprimir
Trabajar en el ISCIII
Agradecimientos